Cited by 397Gestational Diabetes Research and ManagementPregnancy and Medication ImpactPregnancy and preeclampsia studies

Metformin versus placebo in obese pregnant women without diabetes mellitus

Syngelaki, Argyro, Nicolaides, Kypros H., Balani, Jyoti, Hyer, Steve, Akolekar, Ranjit, Kotecha, Reena, Pastides, Alice, Shehata, Hassan·2016·New England Journal of Medicine

Abstract

BACKGROUND: Obesity is associated with an increased risk of adverse pregnancy outcomes. Lifestyle-intervention studies have not shown improved outcomes. Metformin improves insulin sensitivity and in pregnant patients with gestational diabetes it leads to less weight gain than occurs in those who do not take metformin. METHODS: In this double-blind, placebo-controlled trial, we randomly assigned pregnant women without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of more than 35 to receive metformin, at a dose of 3.0 g per day, or placebo (225 women in each group) from 12 to 18 weeks of gestation until delivery. The BMI was calculated at the time of study entry (12 to 18 weeks of gestation). The primary outcome was a reduction in the median neonatal birth-weight z score by 0.3 SD (equivalent to a 50% reduction, from 20% to 10%, in the incidence of large-for-gestational-age neonates). Secondary outcomes included maternal gestational weight gain and the incidence of gestational diabetes and of preeclampsia, as well as the incidence of adverse neonatal outcomes. Randomization was performed with the use of computer-generated random numbers. The analysis was performed according to the intention-to-treat principle. RESULTS: A total of 50 women withdrew consent during the trial, which left 202 women in the metformin group and 198 in the placebo group. There was no significant between-group difference in the median neonatal birth-weight z score (0.05 in the metformin group [interquartile range, -0.71 to 0.92] and 0.17 in the placebo group [interquartile range, -0.62 to 0.89], P=0.66). The median maternal gestational weight gain was lower in the metformin group than in the placebo group (4.6 kg [interquartile range, 1.3 to 7.2] vs. 6.3 kg [interquartile range, 2.9 to 9.2], P<0.001), as was the incidence of preeclampsia (3.0% vs. 11.3%; odds ratio, 0.24; 95% confidence interval, 0.10 to 0.61; P=0.001). The incidence of side effects was higher in the metformin group than in the placebo group. There were no significant between-group differences in the incidence of gestational diabetes, large-for-gestational-age neonates, or adverse neonatal outcomes. CONCLUSIONS: Among women without diabetes who had a BMI of more than 35, the antenatal administration of metformin reduced maternal weight gain but not neonatal birth weight. (Funded by the Fetal Medicine Foundation; ClinicalTrials.gov number, NCT01273584; EudraCT number, 2008-005892-83.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1509819

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Syngelaki, A., Nicolaides, K. H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., Pastides, A., & Shehata, H.
Affiliations
  • Epsom and St Helier University Hospitals NHS Trust (GB)
  • Harris Birthright Research Centre for Fetal Medicine (GB)
  • St Helier Hospital (GB)
  • Medway Maritime Hospital (GB)
Venue
New England Journal of Medicine
Published
2016-02-04
Volume
374
Issue
5
Pages
434-443
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2253351763
Cited by
394
References
33
Citations by year
2026: 17 · 2025: 27 · 2024: 31 · 2023: 25 · 2022: 31 · 2021: 27 · 2020: 39 · 2019: 35 · 2018: 51 · 2017: 90 · 2016: 21
FWCI
84.68
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Keywords
metformin, maternal obesity, pregnancy, gestational weight gain, birth weight, large-for-gestational-age neonates, preeclampsia, gestational diabetes mellitus, insulin sensitivity, adverse pregnancy outcomes, placental growth factor, placental protein 13
MeSH terms
Adult, Birth Weight, Double-Blind Method, Female, Fetal Macrosomia, Humans, Hypoglycemic Agents, Infant, Newborn, Metformin, Obesity, Pregnancy, Pregnancy Complications, Weight Gain, Body Mass Index, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review